Asiaticoside tablets: Asiaticoside tablets 60mg tid for 12 weeks
Study summary
Centella asiatica is a traditional herbal medicine widely used in China and Southeast Asia for treating various conditions. Preclinical studies have shown that madecassic acid glycosides, including asiaticoside and madecassoside, can significantly reduce body weight gain, adipose tissue mass, and serum triglyceride levels in high-fat diet-induced obese mice. These compounds also improve hepatic steatosis and insulin resistance. This exploratory, interventional study aims to evaluate the clinical efficacy of orally administered asiaticoside tablets in adults with overweight or obesity.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Adults aged 18 years or older, male or female.
* Overweight or obesity, defined as a body mass index (BMI) of 24.0-45.0 kg/m².
* Able and willing to provide written informed consent.
Exclusion Criteria:
* Active pulmonary tuberculosis, malignant tumors, human immunodeficiency virus (HIV) infection, or other severe infectious or immunocompromising conditions.
* Severe liver injury (AST or ALT \> 3 times the upper limit of normal) or severe renal dysfunction/end-stage renal disease (eGFR \< 30 mL/min/1.73 m²).
* Severe cardiovascular diseases, including angina pectoris, myocardial infarction, or stroke within the past 6 months.
* Severe gastrointestinal disorders, or a history of gastrointestinal surgery within the past year.
* Secondary causes of obesity, including Cushing's syndrome, primary hypothyroidism, hypothalamic obesity, acromegaly; or drug-induced obesity (e.g., antipsychotics, glucocorticoids).
* Currently receiving other anti-obesity treatments, a previous history of bariatric surgery, or a \>5% reduction in body weight within the past 3 months.
* Current smoker or habitual smoker within the past 3 months.
* type 1 or type 2 diabetes mellitus or currently taking hypoglycemic medications.
* Pregnancy or planning pregnancy, or breastfeeding.
* Unable to complete a 3-month follow-up due to health conditions or relocation.
* Participation in any clinical study within the past 4 weeks.
* Other conditions considered by investigators as unsuitable for participation.
Primary outcome measure(s)
Change in Metabolic Rate — Baseline to Week 4 Metabolic rate will be assessed using indirect calorimetry in a metabolic chamber (whole-room indirect calorimetry) at baseline and Week 4 after taking Asiaticoside tablets.
Change in Body Weight — Baseline to Week 12 Body weight will be measured using a calibrated digital scale at baseline and Week 12 after taking Asiaticoside tablets.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.